On April 19, 2022, Tessera Therapeutics, Inc. closed the transaction. The company has received more than $300,000,000 in the transaction. The transaction included participation from existing investors Alaska Permanent Fund, Altitude Life Science Ventures, new investors a wholly-owned subsidiary of the Abu Dhabi Investment Authority, ARTIS Ventures, Cormorant Asset Management, LP, Flagship Pioneering, Hanwha General Chemical USA Corp., Longevity Vision Fund, a fund managed by Longevity Vision Investment Advisors, LLC, SALT Fund I, L.P., a fund managed by SALT Venture Group, LLC, existing investor SoftBank Vision Fund 2, a fund managed by existing investor SoftBank Investment Advisers (UK) Limited, T. Rowe Price Group, Inc., March Capital Venture Management Services, LLC, the company's founder and others including company's existing investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
108.7 USD | -2.40% | -7.65% | +0.96% |
Apr. 18 | T. Rowe Price says 2018 Tesla pay aligned with investor interests | RE |
Apr. 17 | TD Cowen Adjusts T. Rowe Price Group's Price Target to $112 From $114 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.96% | 24.91B | |
-7.95% | 112B | |
-1.11% | 90.24B | |
+15.14% | 61.07B | |
-0.04% | 58.93B | |
+8.64% | 41.26B | |
+6.15% | 40.73B | |
+17.55% | 34.1B | |
-5.71% | 21.95B | |
+0.37% | 18.45B |
- Stock Market
- Equities
- TROW Stock
- News T. Rowe Price Group Inc.
- Tessera Therapeutics, Inc. announced that it has received $300.000007 million in funding from a group of investors